PDS Biotechnology (PDSB) Interest Expenses (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Interest Expenses came in at $3.1 million in Q4 2025, up 14791.43% YoY from N/an in Q4 2024, and up 165.48% on a QoQ basis from $1.2 million in Q3 2025.
PDS Biotechnology (PDSB) Interest Expenses (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Interest Expenses data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Interest Expenses rose 14791.43% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 107.01% YoY) and the FY2025 annual result came in at $73.4 million, up 13.43% from the prior year.
- Interest Expenses rose to $3.1 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $29.8 million in Q3 2021 to a low of -$20788.0 in Q4 2024.
- A 5-year average of $4.5 million and a median of $1.4 million in 2021 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses jumped 16783.55% — and 2024, when it slumped 101.77%.
- Tracing PDSB's Interest Expenses over 5 years: stood at $43035.0 in 2021, then jumped by 957.03% to $454895.0 in 2022, then jumped by 158.26% to $1.2 million in 2023, then slumped by 101.77% to -$20788.0 in 2024, then soared by 14791.43% to $3.1 million in 2025.
- The last three Interest Expenses figures came in at $3.1 million (Q4 2025), $1.2 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 3.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Mn |
| Jun 30, 2026 | 3.38 Mn |
| Dec 31, 2025 | 3.05 Mn |
| Dec 31, 2025 | 3.05 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 930,878.00 |
| Mar 31, 2025 | 930,878.00 |
| Dec 31, 2024 | -20,788.00 |
| Dec 31, 2024 | -20,788.00 |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |